PMID- 35814202
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - Recent Advances and Perspectives on the Health Benefits of Urolithin B, A 
      Bioactive Natural Product Derived From Ellagitannins.
PG  - 917266
LID - 10.3389/fphar.2022.917266 [doi]
LID - 917266
AB  - Urolithin (Uro) B is a natural compound produced by gut bacteria from ingested 
      ellagitannins (ETs) and ellagic acid (EA), complex polyphenols abundant in foods 
      such as pomegranates, raspberries, blueberries and chestnuts. Uro B has recently 
      garnered considerable attention owing to its wide range of nutraceutical effects 
      and relatively high potency. According to several studies, Uro B prevents the 
      development of hyperlipidemia, cardiovascular disease (CVD) and tumors due to its 
      strong antioxidant and anti-inflammatory properties. Many reviews have 
      systematically summarized the health benefits and pharmacological activities of 
      ETs, EA and urolithins (especially Uro A) while available reviews or detailed 
      summaries on the positive impact of Uro B are rarer. Here, we sought to review 
      the pharmacological activity, mechanism of action, regulation of immune function 
      and its associated diseases and preventive potential of Uro B to elucidate its 
      function as a nutritional agent in humans.
CI  - Copyright (c) 2022 Chen, Guo, Chen, Wu and Zhou.
FAU - Chen, Peng
AU  - Chen P
AD  - Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, China.
FAU - Guo, Zhiei
AU  - Guo Z
AD  - Department of Pharmacy, Wuhan Fourth Hospital, Puai Hospital, Tongji Medical 
      College, Huazhong University of Science and Technology, Wuhan, China.
FAU - Chen, Fuchao
AU  - Chen F
AD  - Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan, China.
FAU - Wu, Yue
AU  - Wu Y
AD  - Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, China.
FAU - Zhou, Benhong
AU  - Zhou B
AD  - Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220622
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC9257173
OTO - NOTNLM
OT  - anti-aging
OT  - antioxidant
OT  - biological effect
OT  - nutritional agent
OT  - urolithin B
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/07/12 06:00
MHDA- 2022/07/12 06:01
PMCR- 2022/06/22
CRDT- 2022/07/11 04:13
PHST- 2022/04/11 00:00 [received]
PHST- 2022/06/06 00:00 [accepted]
PHST- 2022/07/11 04:13 [entrez]
PHST- 2022/07/12 06:00 [pubmed]
PHST- 2022/07/12 06:01 [medline]
PHST- 2022/06/22 00:00 [pmc-release]
AID - 917266 [pii]
AID - 10.3389/fphar.2022.917266 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 Jun 22;13:917266. doi: 10.3389/fphar.2022.917266. 
      eCollection 2022.